GlobeNewsWire
12 Jun 2026, 16:45 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Ronde-cel demonstrated no Grade 3 or higher cytokine release syndrome (CRS) and low rates of Grade 3 or higher ICANS in 108 patients. — Superior safety profiles in CAR-T therapies enable outpatient administration, significantly increasing market competitiveness and patient access.
+0.60Lyell expects to submit a Biologics License Application (BLA) for ronde-cel in the second half of 2027. — Provides a concrete regulatory timeline for potential commercialization, which is a primary value driver for clinical-stage biotech stocks.
+0.50The manufacturing process for ronde-cel has achieved a 97% success rate to date. — High manufacturing reliability reduces operational risk and is critical for scaling cell therapies which often struggle with production consistency.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Translational data indicate that durable responses are linked to CD62L-enriched CAR T-cells with an enhanced memory phenotype. — Biological validation of the drug's mechanism of action increases confidence in the sustainability of clinical efficacy.
+0.30Which stocks this story touches
The company announced positive safety data, high manufacturing success rates, and supportive translational insights for its CAR T-cell therapy candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
4h ago
